High SLFN11 expression is associated with better prognostic groups in AML. (A) Relative SLFN11 messenger RNA expression in normal CD34⁺ cells isolated from healthy donors (n = 12) and in patients with favorable-risk (n = 117) or adverse risk (n = 164) AML based on the ELN 2017 risk criteria. Data were extracted from the Beat AML data set, available through Vizome. (B-D) Relative SLFN11 mRNA expression in patients with (B) newly diagnosed (n = 428) and relapsed (n = 23) AML, (C) de novo (n = 223) and therapy-related AML (tAML) or secondary AML (sAML) (n = 228), and (D) NPM1-mutated (mut) (n = 108) or NPM1 wild-type (WT; n = 340) AML. Data were extracted from the Beat AML data set, and accessed through Vizome. (E) Relative SLFN11 mRNA expression in TP53-WT (n = 117) and TP53-mutated (n = 27) AML. Data were extracted from the OSHU AML cohort using the cBioPortal. (F) Log₂ of SLFN11 mRNA expression in patients with AML with inv(16)/t(16;16) (n = 47), t(11q23)/mixed lineage leukemia (MLL) (n = 42), or a complex karyotype (n = 49). Data were extracted from the TCGA AML data set available through BloodSpot. (G) Relative SLFN11 mRNA expression in normal CD34⁺ cells (n = 32) and patients with (n = 7) or without (n = 444) biallelic CEBPA mutations. Data were extracted from the Beat AML data set available through Vizome. (A,F,G) Statistical analysis was performed using the Kruskal-Wallis test followed by Dunn multiple comparison adjustment. (B-E) Statistical analysis was performed using the 2-tailed Mann-Whitney test. (A-G) The median is represented by the black line for each AML subgroup. ∗P < .05; ∗∗∗P < .001; ∗∗∗∗P < .0001. NS, not significant; RPKM, reads per kilobase million.